tebapivat   Click here for help

GtoPdb Ligand ID: 13106

Synonyms: AG-946 | AG946 | compound 27 [PMID: 38109501]
PDB Ligand
Compound class: Synthetic organic
Comment: Tebapivat (AG-946) is a small molecule activator of pyruvate kinase (PK) [1]. It acts allosterically, at wild type PK and at physiologically relevent PK isoforms (e.g. PKR that's expressed in red blood cells). It is intended to increase PK function in red blood cells with defective glycolysis, as observed in diseases such as myelodysplastic syndromes and sickle cell anaemia.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 136.34
Molecular weight 392.44
XLogP 0.32
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C2=C(C=NN(CC3=CC=CC(=N3)N)C2=O)C4=C1N=C(CC5=NNC=C5)S4
Isomeric SMILES N1N=C(C=C1)CC=2SC3=C(N(C=4C(N(N=CC43)CC5=NC(=CC=C5)N)=O)C)N2
InChI InChI=1S/C18H16N8OS/c1-25-15-12(16-17(25)23-14(28-16)7-10-5-6-20-24-10)8-21-26(18(15)27)9-11-3-2-4-13(19)22-11/h2-6,8H,7,9H2,1H3,(H2,19,22)(H,20,24)
InChI Key DIUOELXIXSCFCR-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
AG-946 was advanced to clinical trial as an investigational PK/PKR allosteric activator.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04536792 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease Phase 1 Interventional Agios Pharmaceuticals, Inc.
NCT05490446 A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) Phase 2 Interventional Agios Pharmaceuticals, Inc.